The clinical impact of phenotype plasticity of cancer stem-like cells becomes visible when examining ALDH1A1 gene expression in different risk groups of AML, and when comparing primary and recurrent disease. The gene discussed is ALDH1A1; the disease is acute myeloid leukemia.